Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

BACKGROUND: IgG replacement therapy (IgRT) in primary immunodeficiencies (PID) is a lifelong treatment which may be administered intravenously (IVIg) or subcutaneously (SCIg), at hospital or at home. The objective of the VISAGE study was to investigate if route and/or place for IgRT impact patients’...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Orphanet J Rare Dis
Main Authors: Bienvenu, B., Cozon, G., Hoarau, C., Pasquet, M., Cherin, P., Clerson, P., Hachulla, E., Crave, J. C., Delain, J. C., Jaussaud, R.
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4917986/
https://ncbi.nlm.nih.gov/pubmed/27334100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-016-0452-9
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki